Cureteq today announces the first of what is planned to be a series of in-licensing deals as the company takes in the compound M8891 from Merck.
New development path for M8891 identified with support from artificial intelligence (AI) platform, and building on strong preclinical and clinical data established by Merck.
Phase 1 study demonstrated acceptable safety and tolerability, and provided preliminary signs of efficacy as monotherapy in patients with solid tumors supporting clinical development of M8891 combination treatments in specific cancer indications.
For setting up meeting at J.P. Morgan 2024, San Francisco
